Erectile dysfunction and premature ejaculation drugs are collected male friends are blessed?

With an ageing population and increased stress at work, male urinary diseases are increasing at a rate of 3% per year, and have become one of the top three killers of men's health in the 21st century.
erectile dysfunction (ED) and premature ejaculation (PE) due to the relatively high incidence, the market prospects are broad, many enterprises have laid out the industry, want to get a piece of it.
domestic anti-super-import, 3 billion market easy-to-master ED, commonly known as "yang", refers to the penis can not continue to achieve or maintain enough erections to complete a satisfactory life, the course of illness for more than 3 months.
a 2010 set of data, the overall prevalence of Chinese mainland ED was 26.1% and that of people over 40 was 46.2%.
if you count 500 million men aged 20 to 70 in the China Statistical Yearbook 2015, there are about 131 million ED patients in China.
The Blue Book of China's Six End Drug Markets shows that china's anti-ED market exceeded 10 billion yuan in the five years from 2012 to 2016, reaching 11.028 billion yuan, with an average annual growth rate of 28.80%.
current treatments for ED include psychotherapy, drug therapy, vacuum narrowing devices (VCDs), sponge injection therapy (ICI), and surgical therapy.
The drugs approved for ED treatment include PDE5 inhibitors (e.g. sedanaf, tadalafa, etc.), dopamine-like astigotides (absinthe), alpha-epinephrine blockers (phenolic lamin), etc., while oral therapy is a first-line drug option for ED patients.
According to the Insight database, a total of 3 PDE-5 inhibitors, namely Sidnaf, Tadalaf and Valdana, have been approved for each variety (see table below).
addition, in addition to ordinary tablets, companies are also developing new dosage forms, such as oral disintegration tablets, oral instant film agents, Pfizer has now launched theacid sidina non-mouth collapse tablets.
of the 3 PDE-5 inhibitors mentioned above, tadala is relatively fast, has the longest effective time (approximately 36 h), and is not affected by a high-fat diet or alcohol intake.
data show that in 2019, the total domestic sales of these three PDE-5 inhibitors exceeded 3.3 billion yuan, a total growth rate of more than 8%.
, in public health facilities, his non-market share has outsold that of West Tyna, which is still the sales champion in retail pharmacies.
among them, in 2019, Baiyunshan's Xidana non-generic drugstore sales in pharmacies have successfully surpassed the original research, successfully occupied the first place, mainly because of the price advantage, fast and wide spread of the speed of the shop and the improvement of doctor-patient education.
relevant clinical data show that the rate of patients with sexual dysfunction in China is less than 10%, mainly due to traditional concept constraints and the lack of a correct understanding of the harm of ED, I believe that with the continuous improvement of doctor-patient education, the public's awareness and attention to ED, ED drug market penetration will also improve.
, according to the Insight database, in addition to the above three PDE-5 inhibitors, domestic enterprises have submitted PDE5 inhibitors Avana non-listing applications.
addition, there are four PDE-5 inhibitors in clinical trials.
expected that in the future, with the approval of new PDE-5 inhibitors on the market, the domestic market of 3 billion will usher in more predators.
Etin's half-price entry into the PE market does not guarantee another common male sexual dysfunction, premature ejaculation (PE), public data show that the incidence of PE among adult men in China is about 33.1%.
, according to the China Statistical Yearbook 2018, there are nearly 300 million men aged 18-64 in China and nearly 100 million PE patients.
treatment includes psychotherapy, behavioral guidance, oral medication, topical medication, urethra administration and penile back nerve cutting, of which drug therapy is the first choice for PE patients.
, according to insight database, only dapostin is currently approved for PE treatment in China.
the drug is the first line of treatment drug in the Guidelines for the Diagnosis and Treatment of Premature Ejaculation at home and abroad.
in 2010 the original research was approved in China, the commodity named Bili Jin.
, according to the Insight database, the minimum specification (30 mg/piece) has a list price of about 70 yuan.
, the company has approved dapoxitin generics in China in April and May of this year, respectively.
the winning bid of 99 yuan/box (30 mg x 3 pieces), far less than Bingli.
addition, there are a number of enterprises layout Dapostine market, of which 6 companies have submitted applications for listing, 4 have conducted BE trials, 2 approved clinical.
also further illustrates the broad prospects of the domestic PE market.
In the end, it is worth mentioning that in the upcoming third batch of national mining, Xidinafei and Dapositin are included, and he Dalafei has already participated in the second batch of national collection, so the welfare of the domestic male compatriots came!